Skip to content
Study details
Enrolling now

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

UNC Lineberger Comprehensive Cancer Center
NCT IDNCT06896162ClinicalTrials.gov data as of Apr 2026
Target enrollment

500

Study length

about 3 years

Ages

18+

Locations

1 site in NC

About this study

This trial is testing whether a precision oncology navigator and expert review of genomic sequencing can help more patients get treatments that are tailored to their specific cancer. The goal is to see if this approach leads to more people enrolling in clinical trials and improves survival rates.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Blood or tissue samples collection
  • 2.Expert Review
  • 3.The Precision Oncology Navigation

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low7%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Secondary: Overall Survival in subjects who are eligible for Level 1/2 genome-informed therapy (GIT), Overall survival (OS), The combined rate of orders for Level 1/2 GIT and consent to biomarker-directed clinical trials, The rates of consent to UNC Health biomarker-selective clinical trials

Body systems

Oncology